I posted about Wedbush many times on this board and examples of blcht ($15!! then rat data!! , No one forced anyone to sell their shares. Most analysts are basing their projections on NTM moving ahead to file because of the FDA being supportive. My USB post is supported by 2 public sites that published the $7 . Would Insmed have to do a dilution to support a Phase3 trial? and many here have OPINED that Insmed would be filing for a mid 2015 + launch.That was their opinion.......No that was a HOPE.There is risk of a Phase3 trial OR as I posted the company might have to ( as Will Lewis also said - "do additional work ( mine more data etc). The clowns like to pump and risk is something they are blinded to. Insmed has risks and if anything, today Wedbush slant maybe woke them up from their stupor
How long does it take for the results to be reviewed and a decision rendered by the FDA? If the results are in and the FDA is reviewing, doesn't someone know the results at the FDA? March is the company word so we have a month of this?
Insmed just gave themselves a CYA timeframe. The review is NOT for approval but just to see if they can file.Insmed has adv because of its status.additional work was my call...we shall see Ok lots of good trades again and you know where we are
Your UBS post was a sham, just like you. You cannot stop Insmed from being a multi billion dollar company and that Terry is why some of us will be rich while you continue to surf the tides of stupidity. Tick,tock.